Recursion Pharmaceuticals, Inc.

RXRX · Healthcare · Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating techn…

Recursion Pharmaceuticals, Inc. (RXRX), in the Healthcare sector, has 26 disclosed filings on Paydirt over the trailing twelve months from 3 corporate insiders: 0 purchases and 26 sales, 2 filed past the deadline. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Sep 1 and filed Sep 2. The most active filer was Christopher Gibson with 27 filings.

Add to watchlist

Filings, ttm

0 buys · 26 sells · 2 late

Traders, ttm

3 insiders

Volume, ttmiDollar value disclosed in the window

$7.8M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Sep 1

Filed Sep 2

ADViAverage daily dollar volume

$67.5M

market data

Share price · 12M

$3.63 (-27.1%)

Adjusted for splits and dividends.

Volume by month

Buys $0 Sells $15.4M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed

Christopher Gibson Director 27 filings BB

Blake Borgeson Director 8 filings NK

Najat Khan Chief R&D Commercial Officer 2 filings MS

Michael Secora Chief Financial Officer 1 filing

Recent filings

Blake BorgesonSALE Director $100K
30,000 sh × $3.34
Exec Sep 1
Filed Sep 2 · 6:01 PM ET Blake BorgesonSALE Director $158K
40,000 sh × $3.96
Exec Jul 7
Filed Jul 9 · 6:04 PM ET Christopher GibsonSALE Director $145K
40,000 sh × $3.62
Exec Jun 5
Filed Jun 5 · 5:30 PM ET Blake BorgesonSALE Director $110K
30,000 sh × $3.68
Exec Jun 2
Filed Jun 4 · 5:30 PM ET Christopher GibsonSALE Director $123K
40,000 sh × $3.08
Exec May 22
Filed May 27 · 5:30 PM ET Christopher GibsonSALE Director $135K
40,000 sh × $3.37
Exec May 7
Filed May 8 · 5:30 PM ET Blake BorgesonSALE Director $106K
30,000 sh × $3.52
Exec May 5
Filed May 7 · 5:30 PM ET Christopher GibsonSALE Director $144K
40,000 sh × $3.61
Exec Apr 22
Filed Apr 24 · 5:30 PM ET Christopher GibsonSALE Director $124K
40,000 sh × $3.10
Exec Apr 7
Filed Apr 8 · 5:30 PM ET Christopher GibsonSALE Director $130K
40,000 sh × $3.25
Exec Mar 23
Filed Mar 25 · 5:30 PM ET Blake BorgesonSALE Director $588K
170,000 sh × $3.46
Exec Mar 3
Filed Mar 4 · 5:30 PM ET Christopher GibsonSALE Director $138K
40,000 sh × $3.46
Exec Feb 19
Filed Feb 19 · 5:30 PM ET Blake BorgesonSALE Director $924K
220,000 sh × $4.20
Exec Feb 3
Filed Feb 6 · 5:30 PM ET † Christopher GibsonSALE Director $165K
40,000 sh × $4.12
Exec Feb 4
Filed Feb 6 · 5:30 PM ET Christopher GibsonSALE Director $179K
40,000 sh × $4.47
Exec Jan 20
Filed Jan 22 · 5:30 PM ET Blake BorgesonSALE Director $959K
220,000 sh × $4.36
Exec Jan 6
Filed Jan 8 · 5:30 PM ET Christopher GibsonSALE Director $170K
40,000 sh × $4.25
Exec Jan 5
Filed Jan 7 · 5:30 PM ET Najat KhanSALE Chief R&D Commercial Officer $549K
124,403 sh × $4.41
Exec Dec 22 2025
Filed Dec 29 2025 · 5:30 PM ET † Christopher GibsonSALE Chief Executive Officer $180K
40,000 sh × $4.50
Exec Dec 19 2025
Filed Dec 19 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $185K
40,000 sh × $4.63
Exec Dec 4 2025
Filed Dec 5 2025 · 5:30 PM ET Blake BorgesonSALE Director $961K
220,000 sh × $4.37
Exec Dec 2 2025
Filed Dec 4 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $166K
40,000 sh × $4.16
Exec Nov 19 2025
Filed Nov 19 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $208K
40,000 sh × $5.21
Exec Nov 4 2025
Filed Nov 6 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $570K
100,000 sh × $5.70
Exec Oct 23 2025
Filed Oct 24 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $604K
100,000 sh × $6.04
Exec Oct 10 2025
Filed Oct 10 2025 · 5:30 PM ET